scholarly journals Emergence of the first manic episode in recovered COVID-19 patients: A case series from Egypt

2021 ◽  
Author(s):  
Hayam M. Elgohary ◽  
Mohammad G. Sehlo ◽  
Usama M. Youssef ◽  
Mohamed Abdelghani
Keyword(s):  
Neuropsychiatric Symptoms ◽  
Gastrointestinal Symptoms ◽  
Case Series ◽  
Manic Episode ◽  
Behavioral Changes ◽  
Future Research ◽  
The Novel ◽  
Manic Symptoms ◽  
Global Pandemic ◽  
Novel Coronavirus

Abstract Objective In December 2019, the novel coronavirus (COVID-19) infection was first reported in Wuhan city, China, which had rapidly spread as a global pandemic. This infection was commonly presented by respiratory and /or gastrointestinal symptoms. However, it is still unclear whether COVID-19 infection could be associated with central nervous system (CNS) damage which would result in development of neuropsychiatric symptoms. Method A total of five cases of suddenly emerged manic episodes during the pandemic of COVID-19 were extensively described. We presented the symptoms and described the diagnosis, clinical course, and treatment of each case. Results All patients had positive findings of ribonucleic acid (RNA) tests for COVID-19 in specimens of their sputum. The patients later developed manic symptoms during and after the recovering period of their illness. Conclusions The case series of newly emerged manic symptoms associated with COVID-19 infection highlights the essential need for evaluation of mental health status and would contribute to our understanding of the potential risk of CNS affection by COVID-19 infection. The limited number of cases would limit the generalizability of association. Future research should investigate the behavioral changes accompanying and following COVID-19 infection.

scholarly journals Respiratory Viral Co-infection with Novel Coronavirus in Children: A Case Series

2020 ◽  
Author(s):  
Emily Hertzberg ◽  
C. Anthoney Lim ◽  
Erick Eiting ◽  
Steven Yung ◽  
Jeranil Nunez ◽  
...  
Keyword(s):  
Clinical Presentation ◽  
Case Series ◽  
Respiratory Viruses ◽  
World Health ◽  
Clinical Implications ◽  
The Novel ◽  
Global Pandemic ◽  
Surgical Evaluation ◽  
Novel Coronavirus ◽  
Health Organization

Abstract Background:The novel coronavirus, COVID-19 was identified in January 2020 initially in Wuhan, China but quickly spread worldwide and was declared a global pandemic by the World Health Organization on March 11, 2020. There are more than 185 countries impacted and the numbers of cases and deaths continues to rise. The rate of coinfections with COVID-19 in children and the clinical implications are unknown.Case Presentation:We describe the clinical presentation and course of three patients with COVID-19 and coinfections with other common respiratory viruses. Two cases were diagnosed with COVID-19 as well as rhinovirus/enterovirus and the third case was COVID-19 and pertussis. Each case had a unique presentations and hospital courses including an emergency room discharge, urgent surgical evaluation and an intensive care unit admission.Conclusions:This is the first US-based case report to discuss coinfections with COVID-19 and other respiratory viruses. Decisions regarding diagnosis and management of children in the setting of the current pandemic should account for the possibility of coinfections. We also highlight publish health challenged resulting from children with the novel coronavirus.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

Infection ◽  
2020 ◽  
Vol 48 (6) ◽  
pp. 871-877 ◽  
Author(s):  
Alessandra Oliva ◽  
G. Siccardi ◽  
A. Migliarini ◽  
F. Cancelli ◽  
M. Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract Introduction The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only two cases of Chlamydia pneumoniae have been reported in a large US study so far. Methods In the present report, we describe a series of seven patients where co-infection with C. pneumoniae (n = 5) or M. pneumoniae (n = 2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. Results and conclusion An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

scholarly journals Practices in Handling Clinical Samples in a COVID-19 Laboratory - An Experience from Chennai, India

2021 ◽  
Vol 10 (39) ◽  
pp. 3508-3510
Author(s):  
Saramma Mini Jacob ◽  
Kanagasabai Sivasangeetha ◽  
Durairaj Anitha ◽  
Singaram Kaplana
Keyword(s):  
Wide Spectrum ◽  
Clinical Manifestations ◽  
Gastrointestinal Symptoms ◽  
World Health ◽  
Clinical Samples ◽  
The Novel ◽  
Global Pandemic ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets

In early January 2020, China had started raising concerns of a new contagious disease caused by new strains of coronavirus, Severe Acute Respiratory SyndromeCoronavirus-2 (SARS-CoV-2). The World Health Organization (WHO) on March 11, 2020, had declared the novel coronavirus (COVID-19) outbreak a global pandemic. COVID-19 was transmitted from person to person through respiratory droplets generated when an infected person coughs, sneezes, breathing or through contact with a surface that has been contaminated 1 and through aerosols-airborne microdroplets.2 The clinical manifestations of COVID-19 represents a wide spectrum of disease ranging from mild to severe respiratory syndrome influenza-like illness with mainly lower respiratory tract symptoms, complicated by pneumonia and Acute Respiratory Distress Syndrome (ARDS), high fever, and headache. In many cases, loss of taste and smell and severe gastrointestinal symptoms were reported, as are cardiac problems, with the latter being perhaps secondary to a cytokine storm such as is seen in the more severely affected patients. 3 WHO COVID-19 dashboard on June 25th 2021 showed 179, 686, 071 confirmed cases worldwide.

scholarly journals COVID-19 in Immunocompromised Cancer Patients: A Case Series and Review of the Literature

2021 ◽  
Vol 28 ◽  
pp. 107327482110443
Author(s):  
Raj H. Patel ◽  
Rachana Vanaparthy ◽  
John N. Greene
Keyword(s):  
Cancer Patients ◽  
Case Series ◽  
The Novel ◽  
Review Of The Literature ◽  
Vulnerable Group ◽  
Potential Threat ◽  
Healthcare Facilities ◽  
Global Pandemic ◽  
Cancer Care Continuum ◽  
Novel Coronavirus

The global pandemic of the novel coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has presented newfound challenges to the oncology community regarding management of disease progression in immunocompromised and cancer patients. Further, the large influx of COVID-19 patients has overwhelmed healthcare facilities, limited access to intensive care unit beds and ventilators, and canceled elective surgeries causing disruptions to the cancer care continuum and re-organization of oncological care. While it is known that the potential threat of infection is greatest in elderly patients (>60 years of age) and patients with underlying comorbidities, there is still insufficient data to determine the risk of COVID-19 in cancer patients. Given the immunosuppressive status in cancer patients arising from chemotherapy and other comorbidities, management of COVID-19 in this patient population carries a unique set of challenges. We report three cases of COVID-19 in immunocompromised cancer patients and discuss the challenges in preventing, diagnosing, and treating this vulnerable group.

scholarly journals Co-infection of SARS-CoV-2 with Chlamydia or Mycoplasma pneumoniae: a case series and review of the literature

2020 ◽  
Author(s):  
Alessandra Oliva ◽  
Guido Siccardi ◽  
Ambra Migliarini ◽  
Francesca Cancelli ◽  
Martina Carnevalini ◽  
...  
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Chlamydia Pneumoniae ◽  
Present Report ◽  
Case Series ◽  
Respiratory Pathogens ◽  
The Novel ◽  
Global Pandemic ◽  
Large Teaching Hospital ◽  
Atypical Pathogens ◽  
Novel Coronavirus

Abstract The novel coronavirus SARS-CoV-2 has spread all over the world causing a global pandemic and representing a great medical challenge. Nowadays, there is limited knowledge on the rate of co-infections with other respiratory pathogens, with viral co-infection being the most representative agents. Co-infection with Mycoplasma pneumoniae has been described both in adults and pediatrics whereas only 2 cases of Chlamydia pneumoniae have been reported in a large US study so far. In the present report, we describe a series of 7 patients where co-infection with C. pneumoniae (n=5) or M. pneumoniae (n=2) and SARS-CoV-2 was detected in a large teaching hospital in Rome. An extensive review of the updated literature regarding the co-infection between SARS-CoV-2 and these atypical pathogens is also performed.

Synthetic and semi-synthetic drugs as promising therapeutic option for the treatment of COVID-19

2020 ◽  
Vol 20 ◽  
Author(s):  
Ekta Shirbhate ◽  
Preeti Patel ◽  
Vijay K Patel ◽  
Ravichandran Veerasamy ◽  
Prabodh C Sharma ◽  
...  
Keyword(s):  
Therapeutic Option ◽  
Antiviral Treatment ◽  
The Novel ◽  
Clinical Experiences ◽  
Synthetic Compounds ◽  
Synthetic Drugs ◽  
Global Pandemic ◽  
The World ◽  
Novel Coronavirus

: The novel coronavirus disease-19 (COVID-19), a global pandemic that emerged from Wuhan, China has today travelled all around the world, so far 216 countries or territories with 21,732,472 people infected and 770,866 deaths globally (as per WHO COVID-19 update dated August 18, 2020). Continuous efforts are being made to repurpose the existing drugs and develop vaccines for combating this infection. Despite, to date, no certified antiviral treatment or vaccine prevails. Although, few candidates have displayed their efficacy in in vitro studies and are being repurposed for COVID-19 treatment. This article summarizes synthetic and semi-synthetic compounds displaying potent activity in their clinical experiences or studies against COVID-19 and also focuses on mode of action of drugs being repositioned against COVID-19.

scholarly journals Management challenges in patients with comorbid COVID-19 associated delirium and serious mental illness – A case series

2021 ◽  
pp. 009121742098597
Author(s):  
Saba Syed ◽  
Michael Couse ◽  
Rashi Ojha
Keyword(s):  
Mental Illness ◽  
Serious Mental Illness ◽  
Healthcare Providers ◽  
Case Series ◽  
Retrospective Chart Review ◽  
Active Management ◽  
The Novel ◽  
Psychiatric Facility ◽  
Medical Teams ◽  
Novel Coronavirus

Background There is still a lot unknown about the novel Coronavirus Disease 19 (COVID-19) and its effects in humans. This pandemic has posed several challenging clinical situations to healthcare providers. Objective We hope to highlight the distinctive challenges that COVID-19 presents in patients with serious mental illness and what steps primary medical teams can take to co-manage these patients with the psychiatry consultants. Methods We present a retrospective chart review of four patients who were on psychotropic polypharmacy and admitted to our hospital from the same long-term psychiatric facility with COVID-19 delirium and other associated medical complications. Results We illustrate how the primary medical teams and psychiatrists collaborated in clinical diagnosis, treatment, and management. Conclusions Patients with serious mental illness and COVID-19 infection require active collaboration between primary medical teams and psychiatrists for diagnostic clarification, reduction of psychotropic polypharmacy to avoid adverse effects and drug-drug interactions, prevention of psychiatric decompensation, and active management of agitation while balancing staff and patient safety concerns.

FEATURES OF THE COURSE AND TACTICS OF MANAGING CHILDREN WITH KIDNEYS AND URINARY TRACT DISEASES DURING THE PANDEMIC OF NEW CORONAVIRUS INFECTION COVID-19

2021 ◽  
Vol 100 (4) ◽  
pp. 74-79
Author(s):  
I.M. Kagantsov ◽  
◽  
V.V. Sizonov ◽  
V.G. Svarich ◽  
K.P. Piskunov ◽  
...  
Keyword(s):  
Age Groups ◽  
Clinical Manifestations ◽  
Routine Care ◽  
The Novel ◽  
Urinary System ◽  
Death Rates ◽  
Global Pandemic ◽  
Coronavirus Infection ◽  
Novel Coronavirus ◽  
Significant Health

The novel coronavirus infection (SARS-CoV-2), which first appeared in Wuhan, China in December 2019, has been declared a global pandemic by WHO. COVID-19 affects people of all age groups. The disease in children is usually asymptomatic or mild compared to adults, and with a significantly lower death rates. Data on kidney damage in children with COVID-19, as well as the effect of coronavirus infection on the course of diseases of the genitourinary system, are limited, the risks of contracting a new coronavirus infection in children with significant health problems, including those with chronic kidney disease, remain uncertain. The pandemic has affected the activities of surgeons treating diseases of the urinary system in children. Since the prospects for the end of the pandemic are vague, it is necessary to formulate criteria for selecting patients who can and should be provided with routine care in the pandemic. The purpose of this review is to highlight the features of the clinical manifestations and treatment of children with COVID-19, occurring against the background of previous renal pathology or complicating its course.

Sign in / Sign up

Export Citation Format

Share Document